CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
erlotinib [Tarceva]drug
Likely dose
erlotinib [Tarceva] 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01174563
NCT01174563Phase 2Completed
CompareCT.gov

A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy

Hoffmann-La Roche·interventional·Posted Aug 3, 2010·Updated Sep 17, 2018

In Brief

A Phase 2 clinical trial evaluating erlotinib [Tarceva] for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 60 participants across 16 sites.

Detailed Summary

This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in participants with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) receiving first-line therapy for advanced disease. Participants will receive Tarceva at a dose of 150 mg daily orally, with dose adjustments according to protocol depending on toxicity. Anticipated time on study treatment is until disease progression, unacceptable toxicity, or withdrawal due to any reason.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesIsrael
CollaboratorsClalit Health Services

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 3, 2010
Enrollment StartMay 23, 2011
Primary CompletionDec 20, 2016
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 15.9 years ago

Interventions

erlotinib [Tarceva]drug

150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol